Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878769 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 20
- Study locations
NCT05878769: Recruiting Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Hoffmann-La Roche.
NCT05878769 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 2,000 participants, above the 1,731-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05878769, a Phase 3 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Conditions Studied
Interventions
- DRUG Astegolimab
Study Locations (20)
Florida
- St Francis Medical Institute ClinEdge PPDS - Clearwater
- Finlay Medical Research Corporation - Greenacres City
- Flourish Research - Leesburg - PPDS - Leesburg
- Advanced Pulmonary Research Institute - Loxahatchee Groves
- San Marcus Research Clinic Inc. - Miami
- Finlay Medical Research Corporation - Miami
- Oceane7 Medical & Research Center, Inc. - Miami
- Research Institute of South Florida Inc - Miami
- Diverse Clinical Research, LLC - Miami
- Central Florida Pulmonary Group, PA - Orlando
- Florida Institute for Clinical Research, LLC - Orlando
Alabama
- UAB Lung Health Center - Birmingham
- SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS - Dothan
- Jasper Summit Research LLC - Jasper
- Pulmonary Associates of Mobile PC - Mobile
California
- Kern Allergy and Medical Research - Bakersfield
- Cadena Care Institute, LLC - Poway
- Apex Clinical Research - San Diego
Arizona
- Pulmonary Associates Deer Valley Office - Phoenix
- AES - DRS - Synexus Clinical Research US, Inc. - Tucson - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What NCT05878769 shows while recruiting
NCT05878769 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,731-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Astegolimab is the first listed.
NCT05878769 names 20 study sites across 4 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05878769 about?
NCT05878769 is a clinical study titled "A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
What is the current status of trial NCT05878769?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2023-06-28. Estimated completion is 2027-06-30.
What conditions does trial NCT05878769 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT05878769?
The interventions under investigation include: Astegolimab (DRUG).
Who is sponsoring clinical trial NCT05878769?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05878769 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05878769's enrollment target sits among peer trials
2,000 8th of 86 higher than 78 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
-
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI